F10 and atrial fibrillation: In the ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) trial, there were more than 21,000 patients with nonvalvular atrial fibrillation, including 2,661 from Latin America.23